Want to see AEON full AI Analyst Report?
AEON Biopharma (AEON) Financial Statements
AEON Biopharma Financial Overview
AEON Biopharma's market cap is currently $16.19M. The company's EPS TTM is $-3.77; its P/E ratio is -0.07; AEON Biopharma is scheduled to report earnings on November 18, 2026, and the estimated EPS forecast is $-0.08. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -12.80M | $ 72.98M | $ -348.09M | $ -48.43M | $ -65.85M |
| EBITDA | $ -16.22M | $ -27.73M | $ -52.74M | $ -52.49M | $ -36.88M |
| Net Income | $ -39.22M | $ 42.01M | $ -384.63M | $ -52.56M | $ -55.64M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.01M | $ 13.00K | $ 5.16M | $ 9.75M | $ 5.13M |
| Total Assets | $ 5.56M | $ 3.14M | $ 6.84M | $ 10.78M | $ 6.44M |
| Total Debt | $ 35.74M | $ 12.96M | $ 278.00K | $ 131.53M | $ 86.89M |
| Net Debt | $ 32.74M | $ 12.94M | $ -4.88M | $ 121.79M | $ 81.76M |
| Total Liabilities | $ 60.59M | $ 31.71M | $ 159.89M | $ 281.19M | $ 230.26M |
| Stockholders' Equity | $ -55.03M | $ -28.57M | $ -153.04M | $ -287.50M | $ -234.94M |
| Cash Flow | |||||
| Free Cash Flow | $ -17.31M | $ -20.29M | $ -47.83M | $ -35.89M | $ -28.60M |
| Operating Cash Flow | $ -17.31M | $ -20.29M | $ -47.83M | $ -35.58M | $ -28.43M |
| Investing Cash Flow | $ -4.00K | $ 0.00 | $ 0.00 | $ -306.00K | $ -170.00K |
| Financing Cash Flow | $ 20.30M | $ 15.15M | $ 14.00M | $ 40.51M | $ 13.56M |
Currency in USD